Vita Life Sciences Limited

Equities

VLS

AU000000VLS8

Pharmaceuticals

Market Closed - Australian S.E. 09:37:39 2024-05-02 pm EDT 5-day change 1st Jan Change
2.26 AUD -0.44% Intraday chart for Vita Life Sciences Limited +0.89% +26.97%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vita Life Sciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023 CI
Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023 CI
Vita Life Sciences Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director CI
Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending 30 June 2023 CI
Vita Life Sciences Limited announces an Equity Buyback for 8,475,692 shares, representing 15% of its issued share capital. CI
Vita Life Sciences Limited's Equity Buyback announced on May 11, 2022, has expired with 208,000 shares, representing 0.37% for AUD 0.34 million. CI
Vita Life Sciences Limited authorizes a Buyback Plan. CI
Vita Life Sciences Limited Announces Demise of Gregory Ralph, Non-Executive Director CI
Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2022, Payable on April 14, 2023 CI
Vita Life Sciences Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022 CI
Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022 CI
Vita Life Sciences Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022 CI
Vita Life Sciences Expects Higher H1 Sales, Pretax Profit MT
Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022 CI
Vita Life Sciences Limited announces an Equity Buyback for 8,325,392 shares, representing 15% of its issued share capital. CI
Vita Life Sciences Limited's Equity Buyback announced on May 28, 2021, has expired. CI
Vita Life Sciences Limited authorizes a Buyback Plan. CI
Tranche Update on Vita Life Sciences Limited's Equity Buyback Plan announced on May 28, 2021. CI
Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022 CI
Vita Life Sciences Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Vita Life Sciences : Expects 20% Increase in 2021 Pretax Profit on Strong Sales; Shares Jump 8% MT
Chart Vita Life Sciences Limited
More charts
Vita Life Sciences Limited (Vita Life) is a pharmaceutical and healthcare company. The Company is involved in formulating, packaging, sales and distributing vitamins and supplements. Its core business is the development and distribution of over-the-counter (OTC) medicines, as well as complementary and alternative medicines, dietary supplements and health foods under various brand names throughout Australia, Malaysia, Singapore, Thailand, Vietnam, China and Indonesia. Its brand portfolio includes Herbs of Gold, VitaHealth, VitaScience and VitaLife. Herbs of Gold brand produces premium herbal, mineral, vitamin and superfood products. VitaHealth brand offers a comprehensive range of nutritional products that cater to every health need, from inner wellness to outer radiance. VitaScience is a vivacious nutritional supplement brand that offers practitioner strength quality formulations. Its subsidiaries include Vita Healthcare Asia Pacific Sdn Bhd, Herbs of Gold Sdn Bhd and others.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. VLS Stock
  4. News Vita Life Sciences Limited
  5. Vita Life Sciences Expects Higher H1 Sales, Pretax Profit